Table 2.
Correlation of clinicopathological parameters and AIB1 protein expression in 129 breast cancer patients
| AIB1 protein (n = 129) | ||||
|---|---|---|---|---|
| negative | positive | p-value | ||
| Age | ||||
| ≤ 50 | 36 | 34 | ||
| > 50 | 32 | 27 | 0.44 | |
| Histological type | ||||
| IDC | 63 | 61 | ||
| non-IDC | 5 | 0 | 0.04 | |
| Histological grade | ||||
| well | 23 | 17 | ||
| moderate | 31 | 31 | ||
| severe | 14 | 13 | 0.76 | |
| T stage | ||||
| T1 | 40 | 38 | ||
| T2 | 26 | 22 | ||
| T3 | 2 | 1 | 0.84 | |
| Lymph node metastasis | ||||
| negative | 41 | 33 | ||
| positive | 27 | 27 | 0.34 | |
| Stage | ||||
| T1 | 33 | 24 | ||
| T2 | 17 | 26 | ||
| T3 | 17 | 9 | ||
| T4 | 1 | 2 | 0.13 | |
| ER | ||||
| negative | 18 | 21 | ||
| positive | 50 | 40 | 0.22 | |
| PR | ||||
| negative | 18 | 23 | ||
| positive | 50 | 38 | 0.12 | |
| HER2 | ||||
| negative | 55 | 39 | ||
| positive | 13 | 22 | 0.02 | |
| AR | ||||
| negative | 17 | 7 | ||
| positive | 51 | 54 | 0.03 | |
| DAX-1 | ||||
| negative | 23 | 9 | ||
| positive | 45 | 52 | 0.01 | |
AIB1: amplified in breast cancer I; IHC: immunohistochemistry; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; and AR: androgen receptor.